public hearing to afford interested persons a further opportunity for the presentation of data, information, and views. In the Commissioner's judgment, the subject matter of this notice is of sufficient importance to justify the use of this additional procedure, as provided in Part 2, Subpart E, of the regulations governing the administrative practice and procedures of the Food and Drug Administration, published in the FEDERAL REGISTER of May 27, 1975 (40 FR 23025).

Interested persons may submit comments on the labeling proposed in this notice by (insert date 60 days after date of publication in the FEDERAL REGISTER). In addition, any interested person may submit data, information, or views in writing any time within 15 days after the conclusion of the public hearing. It is the intention of the Food and Drug Administration to conduct the public hearing prior to the expiration of the time for submitting comments, and the Commissioner therefore encourages interested persons to submit their comments as soon as possible, to allow review prior to the hearing.

After consideration of all written and oral comments and all data, information, and views presented at the public hearing, the Commissioner will promulgate in the FEDERAL REGISTER a final regulation prescribing labeling for oral hypoglycemic drugs, applicable